A Risk-Based Approach to Planning the Elaboration of Pharmacopoeial Monographs
| Autor: | A. V. Yarutkin, V. L. Bagirova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Регуляторные исследования и экспертиза лекарственных средств, Vol 13, Iss 3, Pp 376-384 (2023) |
| Druh dokumentu: | article |
| ISSN: | 3034-3062 3034-3453 1991-2919 |
| DOI: | 10.30895/1991-2919-2023-512 |
| Popis: | Scientific relevance. This article describes a risk-based analysis of the need for elaborating pharmacopoeial requirements for 6 therapeutic groups of medicines, including an evaluation of the range and number of batches of these medicines put into the stream of commerce in the Russian Federation and a comparison of the corresponding product specification files and quality standards. The article presents a set of criteria for planning the elaboration of monographs for the State Pharmacopoeia of the Russian Federation according to a risk-based approach, which is used in a variety of other fields.Aim. The study aimed to develop a comprehensive multivariate risk-based system providing criteria for planning the elaboration of monographs for the State Pharmacopoeia of the Russian Federation.Materials and methods. This study focused on medicines for human use under a range of international non-proprietary names. The authors analysed entries in the Russian State Register of Medicines, data on the number of batches released to the pharmaceutical market, and product specification files and quality standards. The study was conducted using literature search, data analysis, and system-oriented methods.Results. According to the results, a multivariate risk-based analysis is needed for planning the elaboration of monographs for the State Pharmacopoeia of the Russian Federation and the subsequent prioritisation of therapeutic groups or individual medicines for their standardisation.Conclusions. The suggested risk-based system for planning the elaboration of monographs for the State Pharmacopoeia of the Russian Federation includes the following criteria: the social significance of a medicinal product and its value for the health care system; the percentage of medicinal products not tested by the national regulatory authority at the level of active pharmaceutical ingredients; the substantial number of batches and the significant range of medicinal products and the respective active pharmaceutical ingredients by different manufacturers present in the pharmaceutical market; and the analytical procedures and requirements established in product specification files and quality standards. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|